The Latest Breaking News from Pfizer

Pfizer Inc. and partner BioNTech SE have begun submitting data to U.S. regulators for authorization of their COVID-19 vaccine in children 6 months to 4 years old, according to people familiar with the matter, hastening an effort to get shots to younger kids after the omicron wave caused pediatric infections…

The FDA has approved ViiV Healthcare's Apretude (cabotegravir extended-release injectable suspension

The message that Pfizer was not suitable for people with allergies, especially those with a history of anaphylaxis, spread far and wide - but it is simply not true

This blog is now closed

Pfizer is expected to submit a request to the FDA as soon as tomorrow for emergency-use authorization.

U.S. regulators are urging drugmaker Pfizer to apply for emergency authorization for a two-dose regimen of its COVID-19 vaccine for children 6 months to 5 years old

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) are likely to submit a request for an emergency use authorization to the U.S.

Child Covid cases have increased dramatically due to Omicron, yet no vaccine seems on the horizon for this age group

America's oldest ally reveals plan to produce 20 million vaccine doses by years' end, becoming the biomedical center of Africa.